Clinical Trials

18 enrolled

High Risk Non-muscle Invasive Bladder Cancer

NCT07484022 2026-03-19

Study of GB-4362 With Enfortumab Vedotin and Pembrolizumab for Advanced Urothelial Cancer

37 enrolled

Carcinoma, Transitional Cell, Peripheral Nervous System Diseases

NCT02496208 2026-03-18

Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors

152 enrolled

Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Penile Neoplasms, Ureteral Neoplasms, Urethral Neoplasms, Urogenital Neoplasms

NCT03478462 2026-03-18

CLOVER-2

CNSGenitourinaryLymphoidSarcoma

Diffuse Intrinsic Pontine Glioma, Ependymoma, Glioblastoma, Glioma, Hodgkin Disease, Lymphoma, Lymphoma, Non-Hodgkin, Medulloblastoma, Wilms Tumor, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Sarcoma, Synovial, Neuroectodermal Tumors, Primitive, Neoplasms, Neuroepithelial, Gliosarcoma, Rhabdoid Tumor, Desmoplastic Small Round Cell Tumor

NCT04514484 2026-03-18

Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV

BreastDermatologicGastrointestinalGenitourinaryGynecologicSarcomaThoracic

8 enrolled

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Carcinoma, Hepatocellular, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Ovarian Neoplasms, Prostatic Neoplasms, Sarcoma, Kaposi, HIV Infections, Carcinoma, Medullary, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT04963153 2026-03-18

Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and Immunotherapy

24 enrolled

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ureteral Neoplasms, Urethral Neoplasms

NCT05055050 2026-03-18

A Window of Opportunity Phase I Study of UGN-201 in Patients With Bladder Cancer Undergoing Radical Cystectomy Protocol #: 2021-0630

10 enrolled

DermatologicGenitourinaryGynecologicHead & NeckThoracic

Urinary Bladder Neoplasms

NCT06108479 2026-03-18

Study of DF6215 in Patients With Advanced Solid Tumors

Phase 1 Completed

35 enrolled

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Head and Neck Neoplasms, Melanoma, Neoplasms, Ovarian Neoplasms

NCT06439836 2026-03-18

Pembrolizumab Plus CA-4948 for the Treatment of Patients With Progressive Metastatic Urothelial Cancer Despite Prior Immunotherapy

27 enrolled

Carcinoma, Transitional Cell

NCT07424547 2026-03-18

Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors

BreastGenitourinaryGynecologicThoracic

386 enrolled

Breast Neoplasms, Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Small Cell Lung Carcinoma

NCT03258593 2026-03-17

Durvalumab and Vicineum in Subjects With High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated With Bacillus Calmette-Guerin (BCG)

Phase 1 Completed

15 enrolled 21 charts

Urinary Bladder Neoplasms, Carcinoma in Situ

NCT05245006 2026-03-17

PET Imaging Study of 89Zr-DFO-YS5 in Men With Prostate Cancer

Prostatic Neoplasms

NCT06276491 2026-03-17

Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors

282 enrolled

GenitourinaryGynecologic

Testicular Germ Cell Tumor, Neoplasms, Germ Cell and Embryonal, Ovarian Neoplasms, Testicular Neoplasms, Endometrial Neoplasms

NCT06879041 2026-03-17

A Phase I Study of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate Cancer

95 enrolled

Prostatic Neoplasms

NCT07038369 2026-03-17

A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations

BreastGenitourinaryGynecologic

134 enrolled

Breast Diseases, Breast Neoplasms, Uterine Cervical Neoplasms, Genital Neoplasms, Female, Neoplasms, Neoplasms by Site, Ovarian Neoplasms, Prostatic Neoplasms, Urogenital Neoplasms, Uterine Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT07217496 2026-03-17

N-803 in Combination With Pembrolizumab and Enfortumab Vedotin for Treatment of Urothelial Cancer

Phase 1 Withdrawn

Carcinoma, Transitional Cell

NCT04389632 2026-03-16

A Study of Sigvotatug Vedotin in Advanced Solid Tumors

GastrointestinalGenitourinaryGynecologicHead & NeckThoracic

1,006 enrolled

Adenocarcinoma Of Esophagus, Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Esophageal Neoplasms, Ovarian Neoplasms, Stomach Neoplasms

NCT07103018 2026-03-16

STRIKE-001

144 enrolled

Urogenital Diseases, Neoplasm Metastasis, Neoplasms, Neoplasms by Site, Prostatic Diseases, Prostatic Neoplasms, Urogenital Neoplasms, Male Urogenital Diseases

NCT07419841 2026-03-16

A Phase 1 Study of the Safety and Tolerability of CTX-10726

GastrointestinalGenitourinaryGynecologic

70 enrolled

Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Endometrial Neoplasms

NCT02123758 2026-03-13

A Study of JNJ-56021927 (ARN-509) and Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer

57 enrolled

Prostatic Neoplasms

NCT02592317 2026-03-13

A Study to Evaluate the Effect of Multiple Doses of JNJ-56021927 on the Pharmacokinetics of Multiple Cytochrome P450 and Transporter Substrates in Participants With Castration-Resistant Prostate Cancer

23 enrolled

Prostatic Neoplasms, Castration-Resistant

NCT03523442 2026-03-13

A Study of Androgen Receptor (AR) Antagonist Apalutamide in Chinese Participants With Metastatic Castration-Resistant Prostate Cancer

19 enrolled

Prostatic Neoplasms

NCT04004442 2026-03-13

COAXIN

19 enrolled

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ureteral Neoplasms, Urethral Neoplasms

NCT04577833 2026-03-13

A Study of Comparative Formulations of Niraparib and Abiraterone Acetate (AA) in Men With Prostate Cancer

136 enrolled

Prostatic Neoplasms

NCT04644770 2026-03-13

A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer

144 enrolled

Adenocarcinoma, Prostatic Neoplasms

NCT04662580 2026-03-13

ARX517

183 enrolled

Prostatic Neoplasms

NCT05022849 2026-03-13

A Study of JNJ-75229414 for Metastatic Castration-resistant Prostate Cancer Participants

15 enrolled

Prostatic Neoplasms

NCT05567185 2026-03-13

TAR-210

5 enrolled

Acrocephalosyndactylia, Urinary Bladder Neoplasms

NCT05833867 2026-03-13

Adaptive RADiation Therapy With Concurrent Sacituzumab Govitecan (SG) for Muscle Invasive Bladder Cancer

20 enrolled

Localized Muscle Invasive Bladder Urothelial Carcinoma

NCT05843448 2026-03-13

IDO and PD-L1 Peptide Based Immune-Modulatory Therapeutic (IO102-IO103) in Combination With Pembrolizumab for BCG-Unresponsive or Intolerant, Non-Muscle Invasive Bladder Cancer

Urinary Bladder Neoplasms

NCT06173349 2026-03-13

PLZ4-Coated Paclitaxel-Loaded Micelles for the Treatment of Patients With Recurrent or Refractory Non-Muscle Invasive Bladder Cancer

12 enrolled

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT07082920 2026-03-13

A Study of JNJ-78278343 in Combination With JNJ-95298177 for Treatment of Prostate Cancer

140 enrolled

Prostatic Neoplasms

NCT07319871 2026-03-13

A Study of Pasritamig (JNJ-78278343) in Combination With JNJ-86974680 for Treatment of Prostate Cancer

40 enrolled

DermatologicGastrointestinalGenitourinaryGynecologic

Prostatic Neoplasms

NCT03239145 2026-03-12

Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor

Phase 1 Completed

62 enrolled 17 charts

Kidney Neoplasms, Melanoma, Ovarian Neoplasms, Colorectal Neoplasms

NCT05176483 2026-03-12

STELLAR-002

GastrointestinalGenitourinaryHead & NeckThoracic

1,314 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Carcinoma, Hepatocellular, Colorectal Neoplasms

NCT07140315 2026-03-12

DK222 Study at Hopkins

6 enrolled

GenitourinaryThoracic

Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT07416123 2026-03-12

A Study of GEN1106 in Participants With Solid Tumors

103 enrolled

Carcinoma, Transitional Cell

NCT07468396 2026-03-12

A Phase I Clinical Study of GLR2037 in Patients With Advanced Prostate Cancer

65 enrolled

Prostatic Neoplasms

NCT06379217 2026-03-11

NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.

31 enrolled

EndocrineGenitourinary

Metastatic Neuroendocrine Prostate Cancer

NCT07090148 2026-03-11

Trial of pTVG-HP+Nivo+Targeted Ablation of Resistant Lesions in Non-Castrate RecurrentOMPC

14 enrolled

Prostatic Neoplasms

NCT07206225 2026-03-11

A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer

294 enrolled

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT07300241 2026-03-11

Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell, Kidney Neoplasms

NCT07195682 2026-03-10

A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)

125 enrolled

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell, Kidney Neoplasms

NCT06369246 2026-03-09

PRORAD-5 PROstate RADiation in 5 Fractions: Phase II Five Fraction Radiotherapy for Patients With Advanced Prostate Cancer.

70 enrolled

Advanced Prostate Cancer

NCT06533059 2026-03-09

A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors